Contributions
Abstract: PB1360
Type: Publication Only
Session title: Acute lymphoblastic leukemia - Clinical
Background
Post-transplant relapse and graft-versus-host disease (GVHD) remain to be the principal leading causes of failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with adult acute lymphoblastic leukemia (ALL), especially relapse. The degree of methylation of tumor suppressor genes is closely related to the subtypes and prognosis of ALL. Decitabine is one of hypomethylating agents inducing leukemic differentiation and re-expression of epigenetically silenced tumor antigens. The aim of this study was to investigate the safety and efficacy of maintenance treatment with low-dose decitabine after allo-HSCT for adult ALL.
Aims
The aim of this study was to investigate the safety and efficacy of maintenance treatment with low-dose decitabine after allo-HSCT for adult ALL.
Methods
We enrolled 34 patients with ALL who underwent allo-HSCT from August 2016 to April 2020 and gave them low-dose decitabine maintenance treatment after transplantation. GVHD, relapse and overall survival (OS) were observed, and the safety of the regimen was evaluated.
Results
Among the 34 patients enrolled, 32 patients (94.1%) developed only grade I-II myelosuppression, 6 patients relapsed and 6 patients died. The 2-year cumulative incidence of relapse rate (CIR), OS and disease-free survival (DFS) were 20.2%, 77.5% and 73.6%, respectively. The 2-year CIR, OS and DFS of 12 patients with T-ALL/Lymphoblastic Lymphoma (LBL) were 8.3%, 90% and 81.5%, respectively. Among the 7 patients with T-ALL, no one relapsed. During maintenance treatment, only 1 patient (2.9%) developed grade IV acute GVHD and 4 (11.8%) patients had severe chronic GVHD.
Conclusion
Maintenance treatment with low-dose decitabine after transplantation was associated with good tolerance, a low relapse rate without significantly affecting GVHD, and satisfactory survival in patients with ALL, especially patients with T-ALL.
Keyword(s): Acute lymphoblastic leukemia, Decitabine, Maintenance, Post-transplant
Abstract: PB1360
Type: Publication Only
Session title: Acute lymphoblastic leukemia - Clinical
Background
Post-transplant relapse and graft-versus-host disease (GVHD) remain to be the principal leading causes of failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with adult acute lymphoblastic leukemia (ALL), especially relapse. The degree of methylation of tumor suppressor genes is closely related to the subtypes and prognosis of ALL. Decitabine is one of hypomethylating agents inducing leukemic differentiation and re-expression of epigenetically silenced tumor antigens. The aim of this study was to investigate the safety and efficacy of maintenance treatment with low-dose decitabine after allo-HSCT for adult ALL.
Aims
The aim of this study was to investigate the safety and efficacy of maintenance treatment with low-dose decitabine after allo-HSCT for adult ALL.
Methods
We enrolled 34 patients with ALL who underwent allo-HSCT from August 2016 to April 2020 and gave them low-dose decitabine maintenance treatment after transplantation. GVHD, relapse and overall survival (OS) were observed, and the safety of the regimen was evaluated.
Results
Among the 34 patients enrolled, 32 patients (94.1%) developed only grade I-II myelosuppression, 6 patients relapsed and 6 patients died. The 2-year cumulative incidence of relapse rate (CIR), OS and disease-free survival (DFS) were 20.2%, 77.5% and 73.6%, respectively. The 2-year CIR, OS and DFS of 12 patients with T-ALL/Lymphoblastic Lymphoma (LBL) were 8.3%, 90% and 81.5%, respectively. Among the 7 patients with T-ALL, no one relapsed. During maintenance treatment, only 1 patient (2.9%) developed grade IV acute GVHD and 4 (11.8%) patients had severe chronic GVHD.
Conclusion
Maintenance treatment with low-dose decitabine after transplantation was associated with good tolerance, a low relapse rate without significantly affecting GVHD, and satisfactory survival in patients with ALL, especially patients with T-ALL.
Keyword(s): Acute lymphoblastic leukemia, Decitabine, Maintenance, Post-transplant